MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.88 · Revenue $0.00 · 6 analysts
Est. EPS $-0.95 · Revenue $0.00 · 6 analysts
Est. EPS $-3.14 · Revenue $0.00 · 9 analysts
Est. EPS $-0.92 · Revenue $0.00 · 2 analysts
EPS $-0.71 · Revenue $0.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-87.0M | -40.5% | -57.7% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-81.9M | -47.4% | -13.9% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 0.2% | +143.0% | +543.5% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 24.62x | +1.8% | -41.3% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $385.1M | +43.4% | -3.7% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -2.38 vs -2.47 | +3.5% | -0.78 vs -0.63 | -23.3% |
| Revenue Surprise | — | — | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 4, 2026 | Azoulay Salomon | officer: Chief Medical Officer | Common Stock | D | 370 | $65.77 |
| Aug 3, 2026 | Smither John W | officer: Chief Financial Officer | Stock option (right to buy) | A | 130,000 | $64.41 |
| Aug 3, 2026 | Smither John W | officer: Chief Financial Officer | Common Stock | A | 28,000 | — |
| Aug 3, 2026 | Hoerter Steven L. | director, officer: President and CEO | Stock option (right to buy) | A | 331,000 | $64.41 |
| Aug 3, 2026 | Hoerter Steven L. | director, officer: President and CEO | Common Stock | A | 71,000 | — |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Peter Kent Hawryluk | Executive Officer | USD 992,775 | Male | 1969 | Active |
Salomon Azoulay | Chief Medical Officer | USD 734,944 | — | 1958 | Active |
John W. Smither | Chief Financial Officer | USD 642,001 | Male | 1953 | Active |
Steven L. Hoerter | Executive Chairperson, CEO & President | USD 40,477 | Male | 1971 | Active |
Andreas Moraitis | Senior Vice President of Clinical Development | — | — | — | Active |
Mark R. Soued | Chief Commercial Officer | — | Male | — | Active |
Karen Basbaum | Chief Business Officer | — | Female | — | Active |
Michelle Graham | Chief Human Resources Officer | — | Female | 1967 | Active |
Pete De Spain | Senior Vice President of Investor Relations & Corporate Communications | — | Male | — | Active |
Chatan Charan | Senior Vice President of Pharmaceutical Development & Chemistry, Manufacturing and Controls | — | — | — | Active |
Michael A. Dorato DABT | Sr. Vice President of Discovery & Non-Clinical Development | — | — | — | Active |
Mark Hope | Senior Vice President of Regulatory & Quality | — | Male | — | Active |
Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit
Q3 Revenues of $4.1 million and Controlled Net Loss MISSISSAUGA, ON / ACCESS Newswire / August 13, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and nine months of fiscal 2026 ended June 30, 2026 ("Q3" and "YTD"). Results for Q3 and YTD continue to demonstrate the results of the Company's continuing work to rebuild revenues back to profitability following two client setbacks in mid-2025, with revenue growth of 17% in Q3 compared to Q3 fiscal 2025.
MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report) shares hit a new 52-week high during mid-day trading on Thursday after Mizuho raised their price target on the stock from $57.00 to $91.00. Mizuho currently has an outperform rating on the stock. MBX Biosciences traded as high as $66.66 and last traded at $66.46, with a
MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report)'s share price hit a new 52-week high during trading on Friday. The company traded as high as $66.66 and last traded at $61.10, with a volume of 107404 shares trading hands. The stock had previously closed at $63.57. Analyst Ratings Changes A number of analysts have
MBX Biosciences (NASDAQ: MBX - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT - Get Free Report) are both manufacturing companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation. Valuation and Earnings This table compares MBX Biosciences
